Use of Biopsies of Abdominal Subcutaneous Fat to Study the Role of the Activation of Endocannabinoid 1 Receptors (CB1R) on Adipocyte Glucolipid Metabolism

Completed

• Conditions: Hernia Surgery
• Interventions: Procedure: Samples of adipose tissue

• Registration Number: NCT03202706
• Lead Sponsor: Centre Hospitalier Universitaire Dijon

Brief Summary

Obesity is associated with hyperactivation of the endocannabinoid system, and its inhibition by the administration of CB1 receptor (CB1R) antagonists, leads to a decrease in food intake, weight loss and an improvement in metabolic parameters. Even though the reduction in food intake following central CB1R inactivation seems to be the principal cause of weight loss and the improvement in metabolic parameters, several studies in animals and humans have indicated that peripheral CB1R could also be implicated in the regulation of glucolipid metabolism. As a result, it has been suggested that the long-term beneficial effects of inactivation of the endocannabinoid system are due to both central effects on food intake and peripheral effects involving adipose tissue, the liver, skeletal muscle and the pancreas. It appears essential to determine the role of CB1R located in peripheral tissues and in particular in adipose tissue, which plays an active role in maintaining glucolipid homeostasis. The experiments conducted in this project consist in studying in biopsies of abdominal subcutaneous fat whether activation of adipocyte CB1R modifies adipocyte metabolism by determining the mechanisms. The investigators hypothesize that activation of CB1R in adipose tissue will lead to the stimulation of lipolysis dependent on the alteration of the insulin signal, and therefore that inactivation of the endocannabinoid system by blocking peripheral CB1R could constitute a therapeutic approach to improve obesity-related insulin resistance and dyslipidaemia.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-02-24
• Study First Submitted: 2017-06-21
• Study First Submitted QC: 2017-06-26
• Study First Posted: 2017-06-28
• Primary Completion: 2020-01-07
• Study Completion: 2020-01-07
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-21
• Last Update Posted: 2024-02-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 51

Inclusion Criteria

• men aged 18 to 70 years
• persons who have provided oral consent
• persons undergoing surgery for hernia

Exclusion Criteria

• persons without health insurance cover
• BMI > 30
• diabetes
• associated diseases: cancer, chronic inflammatory diseases
• adults under guardianship

obese subjects

Inclusion Criteria:

• men aged 18 to 70 years
• BMI > 30
• persons who have provided oral consent
• persons undergoing surgery for hernia

Exclusion Criteria:

• persons without health insurance cover
• diabetes
• associated diseases: cancer, chronic inflammatory diseases
• adults under guardianship

diabetic obese subjects

Inclusion Criteria:

• men aged 18 to 70 years
• type 2 diabetic not treated with Insulin or GLP-1 agonist
• BMI > 30
• persons who have provided oral consent
• persons undergoing surgery for hernia

Exclusion Criteria:

• persons without health insurance cover
• associated diseases: cancer, chronic inflammatory diseases
• adults under guardianship

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients	Samples of adipose tissue	-

Primary Outcome Measures

Name	Time	Method
Glucolipid metabolism analysis in human abdominal subcutaneous and visceral fat	Baseline

Trial Locations

Locations (1)

CHU Dijon Bourgogne; 🇫🇷 Dijon, France